Website stats for Biopharminternational - biopharminternational.com
Atara Biotherapeutics' MAA for Allogeneic T-cell Immunotherapy Gets EMA ValidationDecember , EMA has fully validated the marketing authorization application for Atara Biotherapeutics’ off-the-shelf allogeneic T-cell therapy, tab-cel (tabelecleucel), with an approval decision expected in .
biopharminternational.com was registered 2 decades 2 years ago. It has a alexa rank of #376,605 in the world. It is a domain having .com extension. It is estimated worth of $ 24,840.00 and have a daily income of around $ 46.00. Furthermore the website is generating income from Google Adsense. As no active threats were reported recently, biopharminternational.com is SAFE to browse.
Traffic Report
| Daily Unique Visitors: | 4,074 |
| Daily Pageviews: | 16,296 |
Estimated Valuation
| Income Per Day: | $ 46.00 |
| Estimated Worth: | $ 24,840.00 |
Search Engine Indexes
| Google Indexed Pages: | Not Applicable |
| Yahoo Indexed Pages: | Not Applicable |
| Bing Indexed Pages: | Not Applicable |
Search Engine Backlinks
| Google Backlinks: | Not Applicable |
| Bing Backlinks: | Not Applicable |
| Alexa BackLinks: | Not Applicable |
Safety Information
| Google Safe Browsing: | No Risk Issues |
| Siteadvisor Rating: | Not Applicable |
| WOT Trustworthiness: |
 Very Poor
|
| WOT Privacy: |
Very Poor
|
| WOT Child Safety: |
Very Poor
|
Website Ranks & Scores
| Alexa Rank: | 376,605 |
| PageSpeed Score: | 89 ON 100 |
| Domain Authority: |
49 ON 100 
|
| Bounce Rate: | Not Applicable |
| Time On Site: | Not Applicable |
Web Server Information
Hosted IP Address:
104.18.196.20
Hosted Country:
US
Location Latitude:
37.7757Location Longitude:
-122.395Traffic Classification
| Total Traffic: | 73.70K |
| Direct Traffic: | 17.63% |
| Referral Traffic: | 0.81% |
| Search Traffic: | 79.66% |
| Social Traffic: | 0.73% |
| Mail Traffic: | 1.17% |
| Display Traffic: | 0% |
Search Engine Results For biopharminternational.com
BioPharm International: Contact Information, Journalists, and Overview
BioPharm International magazine integrates the science and business of biopharmaceutical research, development and manufacturing.
About Us - Process Development Forum
BioPharm International integrates the science and business of biopharmaceutical research, development, and manufacturing. We provide practical peer-reviewed ...
INTERPHEX Keynote Sessions on Wednesday, Oct. 20 - PharmTech
Oct 18, 2021 ... The Pharmaceutical Technology and BioPharm International editors host industry experts in serialization and aseptic processing.
Generic-Drug Makers Also Fight Price Controls - PharmTech
Nov 12, 2021 ... The Democratic legislative proposal to authorize price negotiations on costly medicines covered by Medicare has drawn opposition from brand ...
BioPharm International - CerCell
BioPharm news. www.biopharminternational.com. The Flexibility of Small-Scale Single-Use Bioreactor Solutions. August 1st, 2016 - Volume 29, Issue ...
BioPharm-October 2021-Regulatory-Sourcebook
18 BioPharm International eBook October 2021 www.biopharminternational.com Selecting the Right CMC Strategy for Biologics Smaller biopharma companies must ...
Articles and Publications - BioAssay Sciences
Essentials in Bioassay Design and Relative Potency Determination · BioPharm International · http://www.biopharminternational.com · Published Article ...
ACHIEVING PREDICTABLE BIOPROCESSING RESULTS
- https://faculdadeamazonas.com.br/wp-content/uploads/2021/05/vol-33-3.pdf
BioPharm International integrates the science and business of biopharmaceutical research, development, and manufacturing. We provide practical, peer-reviewed ...
biosimilars_biopharm-intl_aug-2010.pdf - Waters Corporation
16 Supplement to BioPharm International August 2010 www.biopharminternational.com. Advances in Protein Characterization. Biosimilars.
Applying Lessons Learned from the Semiconductor Industry - Avantor
www.biopharminternational.com. November 2019 BioPharm International 25 gle wafer adds to this expense, which is why semiconductor manufacturing.
BioPharm International
BioPharm International is the independent source for technical solutions and business insight for biopharmaceutical research, development, ...
Detection and Clearance of Viruses in the Biopharmaceutical Industry
Dec 17, 2019 ... 27(11) 2014: www.biopharminternational.com/viral-clearance-challenges-bioprocessing. 7 Adair R. Control Viral Contaminants with Effective ...
Benefits of a Revised Approach to Anion Exchange Flow-Through ...
s2 supplement to BioPharm International April 2011 www.biopharminternational.com tion, the available product formats are limited, posing linear scale-up.
BioPharm International Latest Impact Factor IF - Analysis · Trend
BioPharm International · Biotechnology 10% · Pharmaceutical Science 21% · In the Pharmaceutical Science research field, the Quartile of BioPharm International ...
Inline Dilution: An Agile Capability for Downstream Manufacturing
BioPharm International 26, no. 9 (September 2013). http://www.biopharminternational.com/trends-downstream-bioprocessing?pageID=2; 4.
MANAGING BIOMANUFACTURING CAPACITY EXPECTATIONS
- http://images2.advanstar.com/PixelMags/biopharm/pdf/2016-07.pdf
Jul 31, 2016 ... 6 BioPharm International www.biopharminternational.com July 2016. From the Editor. CPhI Pharma. Awards seek nominations for excellence.
BioPharm International - SCImago
BioPharm International integrates the science and business of biopharmaceuticals, covering all aspects of biopharmaceutical research, development, ...
TOT BIOPHARM International - Stock price, News & Analysis
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor ...
Articles - Dyadic International, Inc
BioPharm International, November 1, 2018 ... BioPharmInternational.com, September 20, 2018 ... BioPharm International, August 1, 2018
An Overview of Risk-Assessment Strategies for Extractables and ...
Jan 3, 2012 ... January 2012 www.biopharminternational.com BioPharm International 3. Tutorial. The commercial development of mass spectrometers (MS) of.
DEVELOPMENT STRATEGIES FOR EMERGING THERAPIES 2017
www.biopharminternational.com. eBOOK SERIES. Page 2. 4 BioPharm International eBook September 2017 www.biopharminternational.com.
Optimizing a Unique Cancer Vaccine for Intradermal Delivery
- https://www.goodwinbio.com/wp-content/uploads/2020/12/panacea_-_3m_-_gbi_article_sep_2017.pdf
Goodwin Biotechnology; and DAVE CUNNINGHAM is director, Corporate. Development at Goodwin Biotechnology. www.biopharminternational.com. September 2017.
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
| H1 Headings: | Not Applicable | H2 Headings: | 1 |
| H3 Headings: | 7 | H4 Headings: | 12 |
| H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
| Total IFRAMEs: | 1 | Total Images: | 12 |
| Google Adsense: | pub-7203212329370932 | Google Analytics: | UA-155582410-7 |
Two Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| Personal Information | 2 | 0.749 % | No |
| My Personal | 2 | 0.749 % | No |
| Sell My | 2 | 0.749 % | No |
| Information Privacy | 2 | 0.749 % | No |
| Policy Terms | 2 | 0.749 % | No |
| and Conditions | 2 | 0.749 % | No |
| Terms and | 2 | 0.749 % | No |
| Not Sell | 2 | 0.749 % | No |
| Do Not | 2 | 0.749 % | No |
| Advertise Editorial | 2 | 0.749 % | No |
| Us Advertise | 2 | 0.749 % | No |
| Editorial Information | 2 | 0.749 % | No |
| Information Contact | 2 | 0.749 % | No |
| Us Do | 2 | 0.749 % | No |
| Contact Us | 2 | 0.749 % | No |
| Conditions © | 2 | 0.749 % | No |
| © 2021 | 2 | 0.749 % | No |
| the preclinical | 2 | 0.749 % | No |
| preclinical phase | 2 | 0.749 % | No |
| phase has | 2 | 0.749 % | No |
Four Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| Sell My Personal Information | 2 | 0.749 % | No |
| Not Sell My Personal | 2 | 0.749 % | No |
| My Personal Information Privacy | 2 | 0.749 % | No |
| Personal Information Privacy Policy | 2 | 0.749 % | No |
| Information Privacy Policy Terms | 2 | 0.749 % | No |
| Do Not Sell My | 2 | 0.749 % | No |
| Us Do Not Sell | 2 | 0.749 % | No |
| Advertise Editorial Information Contact | 2 | 0.749 % | No |
| Us Advertise Editorial Information | 2 | 0.749 % | No |
| Editorial Information Contact Us | 2 | 0.749 % | No |
| Information Contact Us Do | 2 | 0.749 % | No |
| Contact Us Do Not | 2 | 0.749 % | No |
| Privacy Policy Terms and | 2 | 0.749 % | No |
| Policy Terms and Conditions | 2 | 0.749 % | No |
| in the preclinical phase | 2 | 0.749 % | No |
| the preclinical phase has | 2 | 0.749 % | No |
| development in the preclinical | 2 | 0.749 % | No |
| drug development in the | 2 | 0.749 % | No |
| Strategizing drug development in | 2 | 0.749 % | No |
| preclinical phase has merit | 2 | 0.749 % | No |
HTTP Header Analysis
Status-Code: 200
Status: 200 OK
Content-Type: text/html; charset=utf-8
Transfer-Encoding: chunked
Connection: keep-alive
cache-control: public, max-age=0, must-revalidate
x-nextjs-page: /index
date: Mon, 06 Dec 2021 06:46:44 GMT
x-powered-by: Next.js
etag: W/"3a092-WLDBbZMJOg7WcA1oq63HdsPwX7Q"
x-vercel-cache: STALE
age: 395
server: Vercel
x-vercel-id: fra1::sfo1::254bh-1638773600416-463b125b513b
strict-transport-security: max-age=63072000
Content-Encoding: gzip
Domain Information
| Domain Registrar: |
CSC Corporate Domains, Inc.
|
|---|---|
| Registration Date: | 2002-07-20 2 decades 2 years 6 months ago |
| Last Modified: | 2021-07-15 3 years 6 months 4 weeks ago |
Domain Nameserver Information
| Host | IP Address | Country | |
|---|---|---|---|
| kiki.ns.cloudflare.com | |
108.162.192.180 | United States |
DNS Record Analysis
| Host | Type | TTL | Extra |
|---|---|---|---|
| biopharminternational.com | A | 294 |
IP: 104.18.200.20 |
| biopharminternational.com | A | 294 |
IP: 104.18.199.20 |
| biopharminternational.com | A | 294 |
IP: 104.18.196.20 |
| biopharminternational.com | A | 294 |
IP: 104.18.197.20 |
| biopharminternational.com | A | 294 |
IP: 104.18.198.20 |
| biopharminternational.com | NS | 86400 |
Target: kiki.ns.cloudflare.com |
| biopharminternational.com | NS | 86400 |
Target: pete.ns.cloudflare.com |
| biopharminternational.com | SOA | 3600 |
MNAME: kiki.ns.cloudflare.com RNAME: dns.cloudflare.com Serial: 2037924131 Refresh: 10000 Retry: 2400 Expire: 604800 |
| biopharminternational.com | TXT | 300 |
TXT: google-site-verification=6qzueLzsZVU6bqz o4UVPk-dMMh1lTMKA3XDL2eUqaDU |
| biopharminternational.com | TXT | 300 |
TXT: amazonses:+e4V3Pg2jBqCd4EVG1bKrA4aMFrmAi yuOb81yWBKNpY= |
| biopharminternational.com | TXT | 300 |
TXT: google-site-verification=QtaHUQGemyk7DiR 0B-iY0Qu_byt6h6xujLM1cwVIAjY |
| biopharminternational.com | TXT | 300 |
TXT: google-site-verification=bDf9VicCF3D2gZD IGmz1HnMBKbBsDpmWzt7lrFJhL7I |
Top Organic Keyword
| 1. | biopharm |
| 2. | hollow fiber bioreactor advantages and disadvantages |
| 3. | tecg transfer and validation |
| 4. | critical process parameters biotechnology |
| 5. | outsource activity risk assessment gmp |
Top Paid Keyword
| Not Applicable |
Full WHOIS Lookup
Registry Domain ID:
88560640_DOMAIN_COM-VRSN
Registrar WHOIS Server:
whois.corporatedomains.com
Registrar URL:
http://cscdbs.com
Updated Date: 2021-07-15T05:10:45Z
Creation
Date: 2002-07-19T17:53:54Z
Registry Expiry Date:
2022-07-19T17:53:54Z
Registrar: CSC Corporate Domains,
Inc.
Registrar IANA ID: 299
Registrar Abuse Contact Email:
[email protected]
Registrar Abuse Contact Phone:
8887802723
Domain Status: clientTransferProhibited
https://icann.org/epp#clientTransferProhibited
Name Server:
KIKI.NS.CLOUDFLARE.COM
Name Server:
PETE.NS.CLOUDFLARE.COM
DNSSEC: unsigned
URL of the ICANN Whois
Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last
update of whois database: 2021-12-05T07:02:36Z
Similarly Ranked Websites
Energía Estratégica | Información en Movimiento, Portal de Noticias
Portal de noticias sobre energías renovables, eficiencia energética y movilidad eléctrica más visitado y actualizado de Latinoamérica.
376,611 
$ 24,840.00
Football Betting Tips & Predictions for all Leagues | Footy...
Footy Accumulators in the number 1 Football Accumulator betting community. Providing Football betting tips, match predictions, football news, free bets, Quizzes and much more!
376,614 $ 24,840.00
GEGAR | Permata Pantai Timur
GEGAR is Malaysia’s No. 1 East Coast radio brand, with a current weekly reach of 2.78M on radio and 1.42M on social media. The brand is the East Coast community’s key source of...
376,619 $ 24,840.00